Leukaemia (chronic myeloid) - imatinib (TA70) (partially updated by TA241 and TA251)
Fast, easy summary view of NICE guidance on 'blood and bone marrow cancers'
The clinical and cost effectiveness of imatinib for first line treatment of chronic myeloid leukaemia
This guidance has been partially updated by TA241 Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant) and TA251 Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib
This guidance updates and replaces NICE technology appraisal 50 (published in October 2002).
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: blood and bone marrow cancers
This page was last updated: 13 February 2014
Information for the public
Implementation tools and resources
- None available
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.